I am interested in advancing the capabilities of biomedical data science, deep learning, and software to improve clinical decision-making and drug discovery. We are pursuing these goals through two complementary approaches: 1) Developing cell morphology as a high-dimensional indicator of cell state through the re-analysis of large microscopy imaging datasets, and 2) Discovering disease vulnerabilities through high-throughput measurements of CRISPR and drug perturbations on biologically relevant cell models.